Know Cancer

or
forgot password


Phase 3
N/A
N/A
Not Enrolling
Both
Pheochromocytoma, Neuroblastoma

Thank you

Trial Information

Inclusion Criteria


- Subject must either have:

1. known or suspected neuroblastoma OR

2. known or suspected phaeochromocytoma

- Subjects are not eligible for the study if they have any clinically active, serious,
life-threatening disease other than neuroblastoma or phaeochromocytoma with a life
expectancy of less than 30 days or where participation in the study might compromise
the management of the subject or other reason that in the judgement of the
investigator(s) makes the subject unsuitable for participation in the study.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

- To demonstrate that 123I-mIBG planar scintigraphy is sensitive and specific in confirming or excluding the diagnoses of neuroblastoma and phaeochromocytoma.

Principal Investigator

Diane McCaul

Investigator Role:

Study Director

Investigator Affiliation:

GE Healthcare

Authority:

United States: Food and Drug Administration

Study ID:

MBG308

NCT ID:

NCT00126412

Start Date:

July 2005

Completion Date:

Related Keywords:

  • Pheochromocytoma
  • Neuroblastoma
  • Phaeochromocytoma
  • Neuroblastoma
  • diagnosis
  • 123I-mIBG
  • Neuroblastoma
  • Pheochromocytoma

Name

Location

GE HealthcarePrinceton, New Jersey  08540